Know Cancer

forgot password

An Endometrial Cancer Chemoprevention Study of Metformin Versus No Treatment in Women With a Body Mass Index (BMI) >/= 35 kg.m2 and Hyperinsulinemia

Phase 3
50 Years
60 Years
Open (Enrolling)

Thank you

Trial Information

An Endometrial Cancer Chemoprevention Study of Metformin Versus No Treatment in Women With a Body Mass Index (BMI) >/= 35 kg.m2 and Hyperinsulinemia

Study Groups:

If you are found to be eligible to take part in this study, you will be randomly assigned
(as in the roll of dice) to 1 of 4 study groups:

- If you are in Group 1, you will receive metformin only.

- If you are in Group 2, you will receive a placebo and lifestyle intervention.

- If you are in Group 3, you will receive metformin and lifestyle intervention.

- If you are in Group 4, you will receive a placebo only.

Neither you nor the study staff will know if you are receiving metformin or placebo.
However, if needed for your safety, the study staff will be able to find out what you are

In the first month you will gradually increase the dose of metformin/placebo by mouth as
listed below:

- Week 1: One capsule each day

- Week 2: One capsule 2 times each day

- Week 3: One capsule 3 times each day

- Week 4: Two capsules 2 times each day

After week 4, you will continue to take 2 capsules of metformin/placebo 2 times each day.

If you are in Group 2 or 3, you will also receive lifestyle intervention. You will have 16
lifestyle intervention sessions over 4 months. At each of these sessions, you will discuss
methods for managing your weight. You will receive print materials and worksheets,
measuring utensils, and a food scale. You will be instructed how to use each of these
materials and how often to use them during the study. You will also be provided with
opportunities for supervised exercise (such as group exercise class and group walks).

If you are traveling during a scheduled session, it can be performed over the telephone.
Each call should last about 30 minutes, during which you will discuss the same goals and
information that you would discuss in the in-person sessions.

Study Visits:

Before you can begin receiving the study drug/placebo:

- You will have a dual energy x-ray absorptiometry (DEXA) scan to measure your body
composition. The scan requires you to lie still on a table for about 8-10 minutes
while a low-energy x-ray takes an image that allows the study staff to get an image of
your body fat density.

- You will be given an accelerometer (a small, portable device that measures your
physical activity) and be taught how to use it at the first Screening Visit. You will
wear the accelerometer at all times while you are awake for 7 days. At the second
Screening Visit, you will return the accelerometer at an intervention session. If you
are not able to return it at the second visit then you will mail it back to the study
staff in a pre-paid envelope. You will receive the accelerometer again at Month 4 and
wear it for another 7 days.

- You will receive a study diary in which you will record any and all exercise you
perform each day while you are on study. It should take about 5 minutes to complete
each time.

- You will complete questionnaires about diet and exercise. These questionnaires should
take about 30-40 minutes to complete.

- You will also be taught to complete a questionnaire on the internet to record the food
you eat in a 24 hour period. You will do this 3 times over a 2 week period. The first
time, you will complete it at the clinic. The study staff will call and remind you to
complete the questionnaire the other 2 times. Each time you complete this
questionnaire, it should take about 40 minutes.

At Month 1, all participants will return for a study visit. The following tests and
procedures will be performed:

- Blood (about 2 teaspoons) will be drawn for routine tests. If this blood draw shows
that your liver or kidney function is abnormal, you will need to return for an
additional blood draw at Month 2.

- You will have a physical exam, including measurement of your height, weight, and waist.

At each month, you will be called and asked about any side effects you may be having. This
phone call should last about 5 minutes. You may be asked about side effects in person if
you are already in the clinic.

Length of Study:

You will receive the study drug/placebo and/or lifestyle intervention for up to 4 months.
You will be taken off study if you have intolerable side effects or if you develop
endometrial cancer or hyperplasia during the study. Your participation in the study will be
over after the end-of-study visit.

Post-Treatment Visit:

At the end of the 4th month, you will have a post-treatment visit. You will repeat all
procedures performed in the first and second visit:

- Your height, weight, waist, and hip circumference will be measured.

- You will have a DEXA scan.

- You will complete the questionnaires about food, diet, and exercise.

- You will have an endometrial biopsy.

- Blood (about 8 tablespoons) will be drawn for routine tests and for biomarker testing.
You will have to fast (not eat or drink anything except water) for 12 hours before this
blood draw.

This is an investigational study. Metformin is FDA approved and commercially available for
the treatment of diabetes and insulin resistance.

Up to 100 patients will take part in this study. All will be enrolled at MD Anderson Cancer

Inclusion Criteria:

1. For this study, only women will be enrolled.

2. Body Mass Index (BMI) > or = 35 kg/m2

3. Not frankly diabetic, as measured by a fasting blood glucose
4. Demonstrate hyperinsulinemia with a QUICK I value below 0.357.

5. Age >/= 50 and
6. Zubrod Performance Scale 0-1

7. Hemoglobin >/= 10 g/dl

8. TSH 0.50 - 5.50mcU/ml

9. Menopause as defined as no menses for 1 year and FSH greater than 50mIU/ml

10. Must be able to read, write, and speak English.

11. Must have a Primary Care Provider (PCP).

Exclusion Criteria:

1. Prior hysterectomy

2. ALT >/r = 2.0x Upper Limit of Normal (ULN)

3. Serum creatinine > /= 1.4 mg/dl

4. Triglycerides (fasting) >/ = 400

5. Known inability to participate in the ongoing appointments for the four months of the
study and scheduled follow-up tests.

6. Significant medical or psychiatric history which would make the participant a poor
protocol candidate, in the opinion of the principal investigator, for any aspect of
study participation including metformin, unsupervised exercise program or dietary
behavior change.

7. Participant reported history of congestive heart failure

8. Prior treatment with Metformin

9. Currently being treated for diabetes or meeting criteria for new diagnosis of

10. Known allergy to Metformin or other biguanide (Proguanil).

11. Use of Aromatase Inhibitors, GNRH-agonists i.e.Lupron, Zoladex within the last 6

12. Use of SERMS (selective estrogen receptor modulators) in the past 6 months, including
Tamoxifen and Raloxifene

13. Hormone replacement therapy within the last 6 months

14. Women who have been treated with chemotherapy for prior malignant disease or
currently have an untreated malignancy other than non-melanoma skin cancer

15. Patients who have had prior radiation to the pelvis

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Effect of Metformin and/or Lifestyle Intervention on Biomarkers.

Outcome Description:

Differences in Ki-67 and other biomarkers analyzed using a 2x2 ANOVA. Other biomarkers examined include a) a panel of genes relevant to estrogen dependent endometrial proliferation, hyperplasia and cancer using Q-PCR, b) biomarkers specific to the effect of metformin treatment (phospho-AMPKa, phospho-ACC, phospho-mTOR and phospho-S6 ribosomal protein and c) potential biomarkers of modulation of insulin sensitivity on the human endometrial proteome using reverse phase protein arrays (RPPA).

Outcome Time Frame:

4 months

Safety Issue:


Principal Investigator

Karen H. Lu, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UT MD Anderson Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

May 2013

Completion Date:

Related Keywords:

  • Gynecology
  • Gynecology
  • Endometrial Cancer Chemoprevention
  • Obese
  • Body Mass Index (BMI) >/= 35 kg.m2
  • Post-menopausal
  • Hyperinsulinemia
  • Metformin
  • Placebo
  • Sugar pill
  • Lifestyle intervention
  • Diet
  • Exercise
  • Endometrial Neoplasms
  • Hyperinsulinism
  • Adenoma



UT MD Anderson Cancer Center Houston, Texas  77030